Radioiodine-refractory thyroid cancer-is it time to change the definition in light of novel redifferentiation therapies?

Affiliations

¹ Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, 10000, Zagreb, Croatia. p.petranovic@gmail.com.
² School of Medicine, University of Zagreb, 10000, Zagreb, Croatia. p.petranovic@gmail.com.
³ Department of Nuclear Medicine and Radiology, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands.
⁴ Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Unit of Nuclear Medicine, University of Messina, 98100, Messina, Italy.
⁵ Division of Nuclear Medicine, Department of Radiology and Nuclear Medicine, University Hospital Magdeburg, Otto-Von-Guericke University, 39120, Magdeburg, Germany.
⁶ Institute Gustave Roussy, 94800, Villejuif, France.
⁷ Department of Nuclear Medicine, Hacettepe University, 06230, Ankara, Turkey.
⁸ Department of Nuclear Medicine, Gruppo Ospedaliero Moncucco SA, Clinica Moncucco, Via Soldino 10, 6900, Lugano, Switzerland.
⁹ Clinic for Nuclear Medicine, University Hospital of Zürich, 8004, Zurich, Switzerland.

Editorial

Petra Petranović Ovčariček et al. Eur J Nucl Med Mol Imaging. 2025 Jan.

. 2025 Jan;52(2):380-385.

doi: 10.1007/s00259-024-06991-5.

¹ Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, 10000, Zagreb, Croatia. p.petranovic@gmail.com.
² School of Medicine, University of Zagreb, 10000, Zagreb, Croatia. p.petranovic@gmail.com.
³ Department of Nuclear Medicine and Radiology, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands.
⁴ Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Unit of Nuclear Medicine, University of Messina, 98100, Messina, Italy.
⁵ Division of Nuclear Medicine, Department of Radiology and Nuclear Medicine, University Hospital Magdeburg, Otto-Von-Guericke University, 39120, Magdeburg, Germany.
⁶ Institute Gustave Roussy, 94800, Villejuif, France.
⁷ Department of Nuclear Medicine, Hacettepe University, 06230, Ankara, Turkey.
⁸ Department of Nuclear Medicine, Gruppo Ospedaliero Moncucco SA, Clinica Moncucco, Via Soldino 10, 6900, Lugano, Switzerland.
⁹ Clinic for Nuclear Medicine, University Hospital of Zürich, 8004, Zurich, Switzerland.

No abstract available

Conflict of interest statement

Declarations. Ethics approval: Not applicable. Competing interests: The authors have no relevant financial or non-financial interests to disclose.

1. Van Nostrand D. Radioiodine Refractory Differentiated Thyroid Cancer: Time to Update the Classifications. Thyroid. 2018;28:1083–93. - DOI - PubMed
1. Giovanella L, Van Nostrand D. Advanced differentiated thyroid cancer: when to stop radioiodine? The Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2019;63:267–70 ( https://pubmed.ncbi.nlm.nih.gov/31271271/ ). - PubMed
1. Schlumberger M, Brose M, Elisei R, Leboulleux S, Luster M, Pitoia F, et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2014;2:356–8. - DOI - PubMed
1. Sacks W, Braunstein GD. Evolving approaches in managing radioactive iodine-refractory differentiated thyroid cancer. Endocr Pract. 2014;20:263–75. - DOI - PubMed
1. De Keizer B, Koppeschaar HPF, Zelissen PMJ, Lips CJM, Van Rijk PP, Van Dijk A, et al. Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin. Eur J Nucl Med. 2001;28:198–202. https://doi.org/10.1007/s002590000443 . - DOI - PubMed